

Table S1: Chronic antibody mediated rejection and death censored allograft survival stratified by group and desensitization therapy.

	Chronic antibody mediated rejection (Banff cg >0)		p-value	Allograft survival		p-value
Group	No eculizumab	+eculizumab		No eculizumab	+eculizumab	
+DSA/low+XM	10/34 (29.4%)	1/2 (50.0%)	P=0.52	33/34 (97.1%)	2/2 (100.0%)	P=1.0
+DSA/high+XM	3/8 (37.5%)	19/35 (54.3%)	P=0.46	6/8 (75.0%)	28/35 (80.0%)	P=0.14
	No bortezomib	+bortezomib		No bortezomib	+bortezomib	
+DSA/low+XM	11/36 (30.6%)	NA		35/36 (97.2%)	NA	
+DSA/high+XM	18/36 (50.0%)	4/7 (57.1%)	P=1.0	29/36 (80.1%)	5/7 (71.4%)	P=0.62